Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq of glioma patient tissues treated by DMSO or LY2109761

ABSTRACT: RNA-seq of glioma patient tissues treated by DMSO or LY2109761

PROVIDER: PRJNA437873 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

miRNA-seq of glioma patient tissues treated by DMSO or LY2109761

Project description:miRNA-seq of glioma patient tissues treated by DMSO or LY2109761

| PRJNA437874 | ENA

miRNA-seq of glioma patient tissues treated by DMSO or LY2109761

Project description:Glioma tissues from patients were cultured in complete DMEM and treated with either DMSO or LY2109761, an inhibitor of TGFBR2. Tissue blocks of TBD0207 and TBD0220 were subjected to miRNA-seq.

2021-03-07 | GSE111675 | GEO

RNA-seq of glioma patient tissues treated by DMSO or LY2109761

2021-03-07 | GSE111674 | GEO

RNA-seq of glioma patient-derived xenografts treated by DMSO or LY2109761

Project description:RNA-seq of glioma patient-derived xenografts treated by DMSO or LY2109761

| PRJNA437856 | ENA

Gene expression of patient derived xenograft glioblastoma treated with DMSO control or Panobinostat.

Project description:Panobinostat is a non-selective histone deactylase inhibitor which has been approved by FDA for treatment of mutiple myeloma. Whether and how the drug works on glioblastoma remains unclear. Here we treated mice implanted with patient derived xenograft glioblastoma G43 with DMSO or Panobinostat and harvest the tumors for microarray analysis for gene expression results.

2019-01-09 | GSE108957 | GEO

Transcriptional changes in glioma cells following treatment with 1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125), Tunicamycin, and 0.1% DMSO (in media)

Project description:Purpose: Evaluate transcriptional changes in glioma derived stem cells, U251, and normal human astrocytes following treatment with NH125, Tunicamycin, or 0.1% DMSO Methods: Glioma derived stem cells, U251 and Normal Human Astrocytes were plated in individual dishes and treated with either 2.5 micromolar NH125, 1.0 mcg/mL Tunicamycin, or 0.1% DMSO (vehicle) for twenty-four hours followed by total RNA extraction, library preparation and next generation sequencing Results: Using our analysis pipeline we mapped our sequence reads to the reference genome GRCh38. Following read count normalization and differential expression of NH125 and tunicamycin treated samples to vehicle treated controls we found that NH125 and tunicamycin treatment lead to activation of similar signalling pathways Conclusions: We present an optimized workflow for analysis of transcriptional changes in drug treated glioma derived stem cells, glioblastoma cells and normal human astrocytes

2018-03-02 | GSE102505 | GEO

Gene expression of patient derived xenograft glioblastoma treated with DMSO control or Panobinostat.

Project description:Gene expression of patient derived xenograft glioblastoma treated with DMSO control or Panobinostat.

| PRJNA429241 | ENA

Gene expression (RNA-Seq) in pediatric high-grade glioma cell lines treated with selinexor and vehicle

Project description:Cultured pediatric high-grade glioma cell lines (SU-DIPG-IV, HSJD-DIPG-007, HSJD-GBM-001,BT 245 (RRID:CVCL_IP13)) were treated with selinexor (Karyopharm Therapeutics) at 5xIC50 for 16 hours or vehicle (0.1% DMSO) followed by bulk RNA-Seq

2020-01-06 | GSE137702 | GEO

Human glioma cells treated with irradiation and/or CCI-779

Project description:Gene expression profiling of human glioma cell line LN-308. Cells were treated with the mTOR inhibitor CCI-779 or irradiated with a single dose of 4 Gy or a combination of both. The objective of this studywas to evaluate CCI-779 as a radio-sensitizing agent and to elucidate the underlying mechanisms. Irradiated, CCI-779-, DMSO- (vehicle control) or combination treated LN-308 samples were hybridized against pooled untreated LN-308 samples as reference (CCI+Irradiation vs. Ref; CCI vs. Ref; DMSO+Irradiation vs Ref; DMSO vs. Ref).Three independent replicates were generated for each treatment and control, respectively.

2011-09-19 | E-GEOD-24232 | biostudies-arrayexpress

RNA-seq of glioma patient-derived xenografts treated by DMSO or LY2109761

Project description:We employed the patient-derived xenografts (PDX) model to test the efficiency of LY2109761 in vivo. The drug was intraperitoneally administered, and the mice were sacrificed on the 31st day. The tumors were excised and subjected to RNA-seq. All groups had similar expression density distributions. Hierarchical clustering showed that the same processing groups had the closest distances.

2021-03-07 | GSE111673 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data